Document Type : Original Article(s)
Authors
- Hossein Babaahmadi-Rezaei 1
- Alireza Kheirollah 1
- Saeed Hesam 2
- Saleh Ayashi 3
- Mohammad Aberumand 1
- Mohammad Hassan Adel 4
- Masoumeh Zamanpour 5
- Maryam Alasvand 6
- Zohreh Amozgari 7
- Mojgan Noor-Behbahani 5
- Zahra Niknam 5
1 Associate Professor, Cellular and Molecular Research Center AND Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Assistant Professor, Department of Biostatistics and Epidemiology, School of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 PhD Candidate, Cellular and Molecular Research Center AND Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4 Associate Professor, Atherosclerosis Research Center AND Department of Cardiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
5 Cellular and Molecular Research Center AND Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
6 Assistant Professor, Atherosclerosis Research Center AND Department of Cardiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
7 Lecturer, Cellular and Molecular Research Center AND Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Abstract
BACKGROUND: Although the antioxidant properties of ginger have been revealed, there is little available information on the effectiveness of ginger on inflammatory disorders such as atherosclerosis. This study was carried out to examine the effect of ginger on improving the complication of atherosclerosis.METHODS: This study was a double-blind, placebo-controlled, randomized clinical trial conducted on patients with atherosclerosis. Participants in the ginger and control groups received 1600 mg of powdered ginger or placebo (wheat flour) in capsules daily for 8 weeks. Weight, body mass index (BMI), fasting blood sugar (FBS), cholesterol, triglyceride (TG), low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), high-density lipoprotein (HDL), lipoprotein (a) [Lp(a)], high-sensitivity C-reactive protein (hs-CRP), and total anti-oxidant capacity (TAC) were assessed before and after the intervention.RESULTS: Ginger consumption in the intervention group significantly reduced serum Lp(a) level (27.25 ± 1.30 ng/ml vs. 23.57 ± 0.97 ng/ml) (P = 0.040) and also the level of hs-CRP in the intervention group was 1.90 ± 0.33 µg/ml and 1.24 ± 0.15 µg/ml (P = 0.010) before and after intervention, respectively, but the levels of Lp(a) and hs-CRP were not decreased significantly in the placebo group. The level of TAC in the ginger group was 0.71 ± 0.05 mM and after the trial was 0.57 ± 0.04 mM (P = 0.050); no significant differences were seen in TAC when ginger was administered at 1600 mg/daily for 60 days. Also the level of Lp(a) and hs-CRP but not TAC reduced significantly in ginger group compared to placebo group after intervention.CONCLUSION: This study showed that ginger had anti-atherosclerosis and anti-glycemic properties associated through a significant decreased Lp(a) and FBS in patients with atherosclerosis supplemented with ginger.
Keywords
- Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352(16): 1685-95.
- Mackay J, Mensah GA. The atlas of heart disease and stroke. Geneva, Switzerland: World Health Organization; 2004.
- Libby P. What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol 2001; 88(7B): 3J-6J.
- Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J 2010; 31(23): 2844-53.
- Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: An analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res 2016; 57(6): 1086-96.
- Kassner U, Schlabs T, Rosada A, Steinhagen-Thiessen E. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options. Atheroscler Suppl 2015; 18: 263-7.
- Kooti W, Mansouri E, Ghasemiboroon M, Harizi M, Ashtary-Larky D, Afrisham R. The Effects of Hydroalcoholic Extract of Apium graveolens Leaf on the Number of Sexual Cells and Testicular Structure in Rat. Jundishapur J Nat Pharm Prod 2014; 9(4): e17532.
- Mitra B, Panja M. High sensitive C-reactive protein: A novel biochemical markers and its role in coronary artery disease. J Assoc Physicians India 2005; 53: 25-32.
- Wang Y, Chun OK, Song WO. Plasma and dietary antioxidant status as cardiovascular disease risk factors: A review of human studies. Nutrients 2013; 5(8): 2969-3004.
- Werneke U, Earl J, Seydel C, Horn O, Crichton P, Fannon D. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 2004; 90(2): 408-13.
- Grzanna R, Lindmark L, Frondoza CG. Ginger--an herbal medicinal product with broad anti-inflammatory actions. J Med Food 2005; 8(2): 125-32.
- Jiang X, Blair EY, McLachlan AJ. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: A population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol 2006; 46(11): 1370-8.
- Frostegard J. SLE, atherosclerosis and cardiovascular disease. J Intern Med 2005; 257(6): 485-95.
- Tietge UJ. Hyperlipidemia and cardiovascular disease: Inflammation, dyslipidemia, and atherosclerosis. Curr Opin Lipidol 2014; 25(1): 94-5.
- Shirali S, Shokri Mashhadi N, Ashtary-Larky D, Safania T, Barari A. Effects of silymarin supplementation on leptin, adiponectin and paraoxanase levels and body composition during exercise: A randomized double-blind placebo controlled clinical trial. Jundishapur J Nat Pharm Prod 2017; 11(4).
- Kooti W, Hasanzadeh-Noohi Z, Sharafi-Ahvazi N, Asadi-Samani M, Ashtary-Larky D. Phytochemistry, pharmacology, and therapeutic uses of black seed (Nigella sativa). Chin J Nat Med 2016; 14(10): 732-45.
- Goyal RK, Kadnur SV. Beneficial effects of Zingiber officinale on goldthioglucose induced obesity. Fitoterapia 2006; 77(3): 160-3.
- Mozaffari-Khosravi H, Talaei B, Jalali BA, Najarzadeh A, Mozayan MR. The effect of ginger powder supplementation on insulin resistance and glycemic indices in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Complement Ther Med 2014; 22(1): 9-16.
- Ali BH, Blunden G, Tanira MO, Nemmar A. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): A review of recent research. Food Chem Toxicol 2008; 46(2): 409-20.
- Sharpe PA, Granner ML, Conway JM, Ainsworth BE, Dobre M. Availability of weight-loss supplements: Results of an audit of retail outlets in a southeastern city. J Am Diet Assoc 2006; 106(12): 2045-51.
- Koba S, Hirano T. Dyslipidemia and atherosclerosis. Nihon Rinsho 2011; 69(1): 138-43.
- Nicoll R, Henein MY. Ginger (Zingiber officinale Roscoe): A hot remedy for cardiovascular disease? Int J Cardiol 2009; 131(3): 408-9.
- Bordia A, Verma SK, Srivastava KC. Effect of ginger (Zingiber officinale Rosc.) and fenugreek (Trigonella foenumgraecum L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 1997; 56(5): 379-84.
- Kooti W, Farokhipour M, Asadzadeh Z, Ashtary- Larky D, Asadi-Samani M. The role of medicinal plants in the treatment of diabetes: A systematic review. Electron Physician 2016; 8(1): 1832-42.
- Shidfar F, Rajab A, Rahideh T, Khandouzi N, Hosseini S, Shidfar S. The effect of ginger (Zingiber officinale) on glycemic markers in patients with type 2 diabetes. J Complement Integr Med 2015; 12(2): 165-70.
- Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102(10): 1082-5.
- Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M, et al. Lipoprotein(a) levels and risk of future coronary heart disease: Large-scale prospective data. Arch Intern Med 2008; 168(6): 598-608.
- Tsimikas S. Lipoprotein(a): Novel target and emergence of novel therapies to lower cardiovascular disease risk. Curr Opin Endocrinol Diabetes Obes 2016; 23(2): 157-64.
- Bos S, Yayha R, van Lennep JE. Latest developments in the treatment of lipoprotein (a). Curr Opin Lipidol 2014; 25(6): 452-60.
- Norata GD, Ballantyne CM, Catapano AL. New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs. Eur Heart J 2013; 34(24): 1783-9.
- Ghafourian M, Ashtary-Larky D, Chinipardaz R, Eskandary N, Mehavaran M. Inflammatory biomarkers' response to two different intensities of a single bout exercise among soccer players. Iran Red Crescent Med J 2016; 18(2): e21498.
- Arablou T, Aryaeian N, Valizadeh M, Sharifi F, Hosseini A, Djalali M. The effect of ginger consumption on glycemic status, lipid profile and some inflammatory markers in patients with type 2 diabetes mellitus. Int J Food Sci Nutr 2014; 65(4): 515-20.
- Mansouri E, Ghasemiboroon M, Asadi Samani M, Alamiri F, Ashtary-Larky D, Kafash Farkhad N, et al. The effect of hydro-alcoholic extract of apium graveolens L. leaf on delivery rate in female rats, weight and gender ratio of infants. Jundishapur J Natur Pharm Products 2017; 12(1): e28802.
- Stoilova I, Krastanov A, Stoyanova A, Denev P, Gargova S. Antioxidant activity of a ginger extract (Zingiber officinale). Food Chem 2007; 102(3): 764-70.
- Kamato D, Babaahmadi Rezaei H, Getachew R, Thach L, Guidone D, Osman N, et al. (S)-[6]-Gingerol inhibits TGF-beta-stimulated biglycan synthesis but not glycosaminoglycan hyperelongation in human vascular smooth muscle cells. J Pharm Pharmacol 2013; 65(7): 1026-36.
)